|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Evet (Yes)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
02.07.2021
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
The Competition Board decision numbered 21-33/446-22 dated 01.07.2021, in relation to the investigation of The Competition Authority against our Company and Gül Ecza Deposu Sanayi ve Ticaret A.Ş, Haver Farma İlaç A.Ş and Sonuç Ecza Deposu AŞ regarding the allegations of "violation of Article 4. of Act No. 4054 on the Protection of Competition by implemention of various practices of Pharmaceuticals Manufacturers and Pharmaceuticals Warehouses in order to jointly determine pharmaceuticals price and sell such pharmaceuticals above the real price in sales to Public Hospitals via tender offers" as was announced by us earlier through a material events disclosure that had been made on 01.07.2021, was received by us on 14.02.2022; and as per this decision, The Board ruled that no violation of competition law has been made by our Company and that no sanctions to be imposed against our Company.
In contradiction between Turkish and English versions of this public disclosure, Turkish version shall prevail.
|
||||||||